| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (frommouse) |
| Target | Proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| Clinical data | |
| Routes of administration | Subcutaneous injection |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6414H9918N1722O2012S54 |
| Molar mass | 145077.18 g·mol−1 |
Bococizumab (USAN;[1] development codeRN316[2]) is a drug that was indevelopment byPfizer targetingPCSK9 to reduceLDLcholesterol.[3] Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."[4]
Bococizumab is amonoclonal antibody that inhibitsPCSK9, aprotein that interferes with the removal ofLDL. LDL levels are a major risk factor forcardiovascular disease.[5]
A phase 2b study ofstatin patients was presented at the 2014 American College of Cardiology.[3] Monthly or bimonthly injections resulted in significantly reducedLDL-C at week 12.
ThePhase 3 SPIRE trials were dose-finding studies and found bococizumab to significantly reduce LDL cholesterol levels, but was commonly associated with anti-drug antibodies. The development of anti-drug antibodies with bococizumab led to an attenuation in LDL lowering at 52 weeks. Wide variation in the relative reduction in cholesterol levels was additionally observed among those not developing antidrug antibodies.[6] After assessing the data, Pfizer abandoned further development of bococizumab.[7]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
